B. Dougherty

发表

Prioritisation of structural variant calls in cancer genomes

O. Hofmann, J. Barrett, D. Stetson, 2016, bioRxiv.

Complexity of FGFR signalling in metastatic urothelial cancer

B. Dougherty, A. Rodriguez-Vida, M. Saggese, 2015, Journal of Hematology & Oncology.

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

R. L. Hollis, A. Biankin, A. Matakidou, 2020, Clinical Cancer Research.

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

O. Hofmann, J. Barrett, J. Dry, 2016, Nucleic acids research.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

D. Matei, J. Ledermann, J. Barrett, 2014, The Lancet. Oncology.

Genes Contributing to Pain Sensitivity in the Normal Population: An Exome Sequencing Study

T. Spector, J. Stephens, S. McMahon, 2012, PLoS genetics.

Genetic Organization of Transposase Regions Surrounding blaKPC Carbapenemase Genes on Plasmids from Klebsiella Strains Isolated in a New York City Hospital

T. Gootz, B. Dougherty, R. Huard, 2009, Antimicrobial Agents and Chemotherapy.

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum

Rebecca F. Halperin, Winnie S. Liang, J. Carpten, 2017, Oncotarget.

A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies

J. Vose, J. Gribben, I. Flinn, 2021, Leukemia & lymphoma.

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.

J. Barrett, D. Hodgson, J. Lanchbury, 2021, Gynecologic oncology.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).

D. Matei, J. Ledermann, C. Scott, 2013 .

Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

J. Barrett, F. André, Paul D. Smith, 2014 .

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

F. Saad, J. Barrett, N. Clarke, 2021, Cancers.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

P. Kristel, C. Caldas, O. Rueda, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2015, British Journal of Cancer.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

E. Kohn, D. Bowtell, A. Oza, 2017, Clinical Cancer Research.

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

H. Mackay, A. Oza, J. Barrett, 2015, The Lancet. Oncology.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

D. Matei, J. Ledermann, J. Barrett, 2014 .

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

Aleksandra Markovets, J Carl Barrett, Geoffrey R Oxnard, 2015, Nature Medicine.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

B. Taylor, M. Berger, S. Chandarlapaty, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice

Miika Ahdesmäki, Justin Johnson, Patrick Pauwels, 2017, Human mutation.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Yeon-Hee Park, D. Stetson, N. Turner, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining actionable mutations for oncology therapeutic development

Jonathan R. Dry, Zhongwu Lai, J. Carl Barrett, 2016, Nature Reviews Cancer.

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

G. Mills, C. Caldas, J. Barrett, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2018, British Journal of Cancer.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

James X. Sun, Roman Yelensky, Zhongwu Lai, 2017, Oncotarget.

Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations inBRCA1orBRCA2are biologically similar and sensitive to PARP inhibition

James X. Sun, R. Yelensky, J. Ledermann, 2015 .

Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance.

Tristan J. Lubinski, J. Barrett, D. Stetson, 2019, JCO precision oncology.

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients

Justin Guinney, Claus Bendtsen, Charles Ferté, 2013, Clinical Cancer Research.

Abstract 4541:METgene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor

S. Signoretti, T. Choueiri, J. Barrett, 2018, Clinical Research (Excluding Clinical Trials).

Generation of stable PDX derived cell lines using conditional reprogramming

Jingwen Zhang, B. Dougherty, C. D’Cruz, 2017, Molecular Cancer.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

Acquired EGFR C 797 S mediates resistance to AZD 9291 in advanced non-small cell lung cancer harboring EGFR T 790 M

Yanan, C. Paweletz, J. Barrett, 2016 .

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

P. Jänne, A. Shaw, L. Crinò, 2015, British Journal of Cancer.

Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer.

E. Wherry, T. Slidel, G. Kar, 2021, The Journal of clinical investigation.

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

R. L. Hollis, A. Okamoto, A. Matakidou, 2022, medRxiv.

Abstract 2398: Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic

J. Barrett, Y. Bang, C. Harbron, 2014 .

Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer.

J. Barrett, D. Hodgson, S. Im, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).

J. Barrett, Y. Bang, D. Hodgson, 2016 .

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient 1 stratification 2

R. L. Hollis, A. Okamoto, A. Matakidou, 2022 .

Prioritisation of structural variant calls in cancer genomes

Oliver Hofmann, Pablo Cingolani, Brad A. Chapman, 2016, bioRxiv.

Generation of stable PDX derived cell lines using conditional reprogramming

Jingwen Zhang, B. Dougherty, C. D’Cruz, 2017, Molecular Cancer.

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

H. L. Wright, R. Moots, T. Spector, 2013 .

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

H. Mackay, A. Oza, M. Friedlander, 2015, The Lancet. Oncology.

Edinburgh Research Explorer Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma

R. L. Hollis, A. Biankin, A. Matakidou, 2022 .

Rare variant associations with plasma protein levels in the UK Biobank

J. Harrow, R. Dhindsa, I. Tachmazidou, 2023, Nature.